

**GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022,
[SPEAKER BIOGRAPHIES]**



Dr. Smita Banerjee is an Associate Attending Behavioral Scientist in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center. Her research is in cancer prevention and control, with special emphasis on the role of communication between oncology health care providers (HCPs) and patients, and message framing for cancer risk prevention. Her recent work has primarily been contextualized in the areas of communication skills training to (a) reduce stigma experienced by patients with lung cancer who smoke(d), (b) improve sexual and gender minority (SGM) sensitivity for oncology HCPs, and (c) encourage HCPs to discuss sexual health concerns of cisgender female patients with cancer. Dr. Banerjee's research has been funded by the NCI, NIDA, and philanthropic organizations like T. J. Martell Foundation, Goldstein Foundation, and Geri & Me Foundation. She has published over 95 peer-reviewed manuscripts, 15 reviews and book chapters, and presented in over 100 national and international conferences.



Dr. Sigrid Collier is a board-certified dermatologist and an Acting Instructor in the Division of Dermatology at the University of Washington. Dr. Collier's research focuses on improving access to care for people with HIV-associated skin diseases, including Kaposi's sarcoma. Much of her current work uses implementation science methods to understand and improve delays in the Kaposi's sarcoma care cascade in East Africa. This includes using mixed methods approaches to understand role of stigma and social support in the diagnosis and treatment of Kaposi's sarcoma.



Dr. Andrew Dykens is an Associate Professor of Family and Community Medicine at the University of Illinois at Chicago (UIC) and the Director of Global Health Equity Implementation Research at the UIC Center for Global Health who studies the implementation of sustainable cervical cancer screening programs in Senegal. Andrew is the Founder and Director for the Capacity Building Platform at the Consortium of Universities for Global Health, a global initiative that aims to facilitate institutional partnerships focused on health capacity building by connecting locally identified human resource gaps to existing training capacity.

GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022, [SPEAKER BIOGRAPHIES]



Dr. Thomas Fitzpatrick is an infectious diseases fellow at the University of Washington. His clinical and research focus is improving care for people who use drugs. His research includes the development of community-based interventions to improve outcomes for the infectious complications of drug use, including optimizing the viral hepatitis care continuum. This work includes stigma reduction efforts to help people who use drugs better engage in care.



Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program, a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center and a Member of the Faculty at Harvard Medical School. In 2022, Dr. Florez also became the first Latina to hold an Associate Editor position in oncology as the new Associate Editor for Diversity, Equity and Inclusion at the JAMA Oncology Journal. She is originally from Venezuela. Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date

evaluating sexual dysfunction in women with lung cancer.

Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in cancer health disparities, gender and racial discrimination in medical education and medicine. Dr. Florez is one of the co-founders of the Twitter community #LatinasInMedicine, now composed of over 8,500 members globally. She received many awards, including the 2018 Resident of the Year Award by the National Hispanic Medical Association, 2019 the Mayo Brothers Distinguished Fellowship award, the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology, and the 2021 International Association for the Study of Lung Cancer (IASLC) North America Cancer Care Team Award for outstanding clinical care.

In addition, Dr. Florez founded the Florez (formerly Duma) Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine and medical education. The laboratory long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change. Since its foundation, the Duma laboratory has received research funding from several national agencies, published over 30 studies and editorials.

**GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022,
[SPEAKER BIOGRAPHIES]**



Dr. Esther Freeman is Director of Global Health Dermatology at Massachusetts General Hospital, Harvard Medical School, USA. She also serves as the Director of Clinical Innovation and Education at Massachusetts General Hospital's Center for Global Health and is Associate Professor of Dermatology at Harvard Medical School. Her research interests include HIV-associated malignancies, burden of skin disease in resource-limited settings, and intersectional stigma in the setting of HIV, cancer, and skin disease. She is a board-certified dermatologist and PhD trained epidemiologist.



Dr. Satish Gopal is the director of the Center for Global Health (CGH) at NCI. In this role, he oversees the development of initiatives and collaborations with other NCI divisions, NCI-Designated Cancer Centers, and countries to support cancer research and cancer research networks, promote cancer control planning, and build capacity in low- and middle-income countries. Before joining NCI, Dr. Gopal was the Cancer Program director for the University of North Carolina (UNC) Project-Malawi, in collaboration with the Malawi Ministry of Health.

As an extramural investigator, his NIH-funded research program focused on epidemiologic, clinical, and translational studies of lymphoma and HIV-associated malignancies in sub-Saharan Africa, and he also oversaw a broad, multidisciplinary cancer research portfolio addressing many of the commonest cancers in the region, including cervical, breast, and esophageal cancer. He also served as the associate chair for African International Sites for the NCI AIDS Malignancy Consortium (AMC) and had oversight responsibility for African activities of the AMC, which was the first NCI cooperative clinical trials group to conduct multicenter interventional studies for cancer in the region.



Dr. Dylan Graetz is a pediatric oncologist and Assistant Professor at St. Jude Children's Research Hospital where she directs the Culture and Communication program within the department of Global Pediatric Medicine. Dr. Graetz's research focuses on how cultural context impacts interactions between pediatric cancer patients and families, and their healthcare teams. Through her work, Dr. Graetz aims to understand and enhance communication practices and patient-centered care of pediatric oncology patients in global settings, as well as interdisciplinary communication of healthcare teams. Dr. Graetz's work spans the globe including ongoing studies in the United States, Guatemala, Pakistan,

Jordan, Zimbabwe, and the Philippines. Clinically, Dr. Graetz treats children with solid tumors with a specific focus in renal cancers.

GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022, [SPEAKER BIOGRAPHIES]



Dr. Megan Huchko is the Hollier Family Associate Professor of Global Health and Obstetrics & Gynecology, Director of the Center for Global Reproductive Health and the Associate Chief of Research for the Division of Women's Community and Population Health at Duke. She has been working in collaboration with the Kenya Medical Research Institute (KEMRI) since 2006 to develop infrastructure for clinical and implementation research and research training in areas of western Kenya with high HIV prevalence. Dr. Huchko's research focuses on optimizing the diagnosis and treatment of cervical cancer among vulnerable populations in the US and low-resource settings, including women living with HIV. Currently, she is carrying out several large studies in central Uganda and western Kenya to evaluate the optimal implementation strategy for HPV-based cervical cancer screening and vaccination in rural settings. She works in partnership with ministries and government officials in both places to develop and evaluate sustainable and context-specific prevention strategies. She recently completed work on a Fogarty-funded R21 to develop a framework and measurement tool for intersectional stigma related to HPV, cervical cancer, and HIV. Her team just launched a three-year follow-up study to finalize and test a pilot a stigma-responsive implementation strategy for HPV-based screening.



Dr. Sonali Johnson is Head of Knowledge, Advocacy and Policy at the Union for International Cancer Control. Her main area of work is to ensure that cancer prevention, treatment, and care is positioned within the global health and development agenda, including plans for universal health coverage (UHC). During her professional career, Dr Johnson has worked on a range of public health issues including cancer control, gender and HIV/AIDS, reproductive and sexual health, gender-based violence, knowledge translation, and health and human rights. In addition, she served twice as a member of the Ethics Review Committee (ERC) of the World Health Organisation.

Dr. Johnson holds a PhD and post-doctorate diploma in public health and policy from the London School of Hygiene and Tropical Medicine and an MSc in Gender and Development from the London School of Economics and Political Science.



Ms. Benda Kithaka is the Executive Director of KILELE Health Association - a Kenyan Non-Profit that equips patients, survivors, and caregivers to use lived experiences as tools for policy advocacy, community education, and behaviour change communications. The team is working to reduce stigma and support NCDs prevention across Kenya for improved quality of life. As a Health Communications and Advocacy Specialist Benda offers Technical Assistance to various health institutions, including the World Health Organisation (WHO), Union for International Cancer Control (UICC), American Cancer Society (ACS), and the Ministry of Health in Kenya in project management, partner and stakeholder liaison, and championing

**GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022,
[SPEAKER BIOGRAPHIES]**

collaborations for cervical cancer elimination. She is also the current Chair of the 2022-2023 Africa Cancer Research and Control ECHO Steering Committee.

Benda is passionate and committed to policy and patient advocacy, with a special interest in community ownership of health for prevention. Twice, Benda has led teams of cancer survivors and caregivers, many from informal settlements [low-income households] to overcome their self-limiting beliefs and climb Mt. Kenya, and once up Mt. Kilimanjaro; showcasing that there is life beyond a cancer diagnosis.



Dr. William Klein was appointed Associate Director of the National Cancer Institute's (NCI) Behavioral Research Program (BRP) in August 2009. Dr. Klein's research interests fall largely under the areas of self-judgment, risk perception, and risk communication. He has been interested in how risk perception biases are related to the processing of health communications, to health decision-making, and to health behavior; how social processes (e.g., social comparison, self-affirmation, peer influence) influence responses to personalized feedback and risk communication; the influence of affective factors such as worry on risk appraisal and health decisions; the impact of ambiguity on responses to

feedback and risk messages; the role of optimism in health behavior and psychological functioning; and applications of theory to risk communication and health behavior intervention. In recent work he has been particularly interested in genetic testing decisions.

Dr. Klein is currently adjunct faculty at the University of Pittsburgh and Johns Hopkins University, and an adjunct investigator at the National Human Genome Research Institute where he collaborates on several projects involving genetic risk communication. He is a member of the Executive Committee of the joint NIH/Hopkins Genetic Counseling graduate program in which he teaches a graduate course on health judgment and decision making. Dr. Klein co-chairs the Cognitive, Affective, and Social Processes in Health Research (CASPHR) working group at NCI and is vice chair of an interagency workgroup focusing on behavioral and social science research. He was a recipient of the American Psychological Association's Meritorious Research Service Commendation, the Social Personality Health Network's Career Service Award, and three NCI Merit Awards.



Dr. Chigozie Nkwonta is a post-doctoral fellow in the Behavioral Science Training Program at New York University; and an adjunct faculty in the College of Nursing, Walden University. Collectively, she has 14 years' experience in clinical Nursing, Teaching and Research. Her research focuses on the impact of intersectional stigmas on HPV and Cervical Cancer prevention, HIV treatment, socio-behavioral aspect of health and gender relations --with experience and expertise in global health.

**GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022,
[SPEAKER BIOGRAPHIES]**



Dr. Laura Nyblade is a Fellow and Senior Technical Advisor on Stigma and Discrimination in the division for global health, in the international development group, RTI International. For the past two decades, she has built and led a portfolio of research and programmatic work on HIV stigma with a focus on data utilization to support evidence-based program implementation and policy at local, national, and global levels. Working in close collaboration with civil society and governments across Sub-Saharan Africa, South and South-East Asia and the Caribbean, Dr. Nyblade has led the design, roll out and evaluation of evidence-based HIV stigma reduction programs, the development of programmatic tools to engage multiple audiences, and the development and validation of stigma measures.

Building on her two decades of HIV stigma research and programmatic work, Dr. Nyblade is expanding her HIV stigma research and intervention work to focus on intersectional stigma. She is also interested in how learning from global stigma intervention research can be leveraged for stigma-reduction programming in the US.

In addition, Dr. Nyblade’s research and programmatic interests include health stigma more broadly and exploring where commonalities may exist that can be leveraged for a more efficient and effective response to health stigma, either through translations of lessons learned around one health stigma to another or through joint intervention research programs that tackle multiple health stigmas together. In this area of work, Dr. Nyblade is currently leading a sub-working group on hearing loss stigma under the Lancet Commission on Hearing Loss, as well as exploring cancer stigma.



Dr. Jamie Ostroff is the Chief, Behavioral Sciences Service, Vice Chair for Research, Director of the Tobacco Treatment Program and Co-Program Leader for the Population Science Research Program at MSKCC. She is a Professor in the Department of Psychiatry and the Department of Population Health at the Weill Cornell Medical College of Cornell. Over the past three decades, her professional career has been focused broadly on advancing knowledge of the psychological and behavioral issues associated with prevention, early detection and long-term follow-up care of patients diagnosed with lung, head and neck and other tobacco-related cancers. She has specific expertise in the development, evaluation, and implementation of theory-driven, multi-level

tobacco treatment interventions in cancer and other health care settings. As an outgrowth of her tobacco control work, she and her colleagues have more recently developed a keen interest in understanding the causes and consequences of lung cancer stigma as a foundation for the development and testing of multi-level interventions to prevent and mitigate lung cancer stigma. She has a strong track record of national citizenship as evidenced by her prior service on the NCI/AACR Task Force on Assessment of Tobacco Use, the Go2 Foundation for Lung Cancer’s Scientific Leadership Board, and the National Lung Cancer Roundtable of the American Cancer Society. In 2022, she was recognized as a Distinguished Scientist by the Cancer Special Interest Group of the Society for Behavioral Medicine.

GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022, [SPEAKER BIOGRAPHIES]



Mr. Jim Pantelas is a 17-year late-stage lung cancer survivor, a Navy veteran, a father, and a research advocate. He has worked with NIH/NCI, FDA, PCORI, CDMRP, University of Michigan and others to help assess, progress, and oversee cancer research both nationally and locally.



Dr. Anne Stangl is the Senior Advisor for the Elimination of Stigma and Discrimination in the Division of Global HIV and TB at the U.S. Centers for Disease Control and Prevention. She is also Associate Faculty with the Department of International Health at the Johns Hopkins Bloomberg School of Public Health. She has 20 years of international public health experience in Africa, Asia and the Caribbean. Her research focuses on understanding and addressing the social and structural determinants of health, including intersectional stigma, that impede access to and uptake of health services among underserved populations globally. Dr. Stangl is a leading expert on health-related stigma and discrimination and has contributed to theoretical understanding of how the stigmatization process operates in the context of health. She is also actively engaged in utilizing research findings to inform global policy and action.



Dr. Jamie L. Studts is a Professor of Medical Oncology at the University of Colorado School of Medicine and Scientific Director of Behavioral Oncology. Dr. Studts also serves as the Co-Leader for the Cancer Prevention and Control program and Co-Director of the Population Health Shared Resource at the University of Colorado Cancer Center. Prior to joining the University of Colorado, Dr. Studts served as Professor of Behavioral Science at the University of Kentucky College of Medicine, Assistant Director for Cancer Prevention and Control, and Director of the Behavioral and Community-Based Research Shared Resource Facility at the University of Kentucky Markey Cancer Center. Dr. Studts is a licensed clinical health psychologist, and his interests address behavioral aspects of tobacco-related malignancies. His research develops and tests interventions to promote informed/shared decision making and behavior change among patients and clinicians regarding prevention, screening, and survivorship of lung and head/neck cancer. Dr. Studts is the Principal Investigator of the Kentucky LEADS Collaborative, and he previously served on the Institute of Medicine National Cancer Policy Forum addressing Implementation of Lung Cancer Screening. He is a Fellow of the Society of Behavioral Medicine, a member of the Scientific Leadership Board for the GO₂ Foundation for Lung Cancer, and the National Comprehensive Cancer Network's Lung Cancer Screening and Smoking Cessation Guideline Panels. Dr. Studts serves as a member of the Steering Committee for the American Cancer Society's National Lung Cancer Roundtable and Chairs the Survivorship, Stigma, and Nihilism Task Group. Recently, Dr. Studts joined the Steering Committee for

GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022, [SPEAKER BIOGRAPHIES]

the Lung Ambition Alliance. In 2019 he received the Centerstone Healthcare Advocacy award in recognition of his efforts to reduce the burden of lung cancer in Kentucky.



Ms. Carolyn Taylor is a photographer, a supportive cancer care advocate and a survivor of ovarian and endometrial cancers. In 2010, after winning a grant from British Airways, she logged more than 120,000 air miles, visiting 14 countries using photography and interviews to document that regardless of race, religion, nationality, or economic status, we are all one in the battle against cancer. Inspired by the people she met and the lack of support we tend to take for granted in high-resource settings, Carolyn founded Global Focus on Cancer (GFC), a non-profit organization in late 2011 to act as an agent of simple and effective change to help reduce the global burden of cancer through programs in cancer support, awareness, education, advocacy and networking in countries where access to information about cancer is critically lacking. In addition to being its founder, she is currently serving as GFC's Executive Director. She leverages her networking skills to develop broad-based partnerships and build strong alliances among clinicians, MOH's, NGO's, advocacy groups, industry and private sector to introduce meaningful and lasting evidence-based, cancer awareness and supportive initiatives across resource settings. Carolyn serves as a content expert with the Women's Empowerment Cancer Advocacy Network, sits on ASCO's Gynecologic Cancer Guidelines Committee and a Measures Panel, was a contributing author to the Lancet series 'Health, Equity and Women's Cancers' along with additional publications. She is also an advisor to the Lancet Commission on Women and Cancer. Carolyn is a frequent speaker/moderator at global cancer conferences and since 2015, has served as the co-founder and co-chair of the annual SE Asia Breast Cancer Symposium.



Dr. Emily S. Tonorezos serves as director of the Office of Cancer Survivorship, part of the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). In this position, Dr. Tonorezos leads NCI's efforts to address the challenges facing cancer survivors and their families -- to prevent or mitigate adverse effects and to improve the health and well-being of cancer survivors from the time of diagnosis through the remainder of their lives.

Dr. Tonorezos came to NCI from Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College, both in New York, NY, where she served as director of the Adult Long-Term Follow-Up Program for survivors of childhood and young adult cancers. Her research, which has been funded by the National Cancer Institute, the American Cancer Society, the American Institute of Cancer Research, and others, focuses on cardiometabolic consequences of cancer therapy, childhood and young adult cancer survivorship, diet and nutrition, and care coordination for this population. She serves as Obesity and Diabetes Mellitus Silo leader for the Children's Oncology Group (COG) Long-Term Follow-Up Guidelines and as co-leader of the International Guideline Harmonization Group for the metabolic syndrome. She also has served on the National Academy of Sciences, Engineering and Medicine

GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022, [SPEAKER BIOGRAPHIES]

Committee on Childhood Cancer and Disability and on the Cancer Survivorship Committee, the Adolescent and Young Adult Task Force, and the Clinical Guideline Committee for the American Society of Clinical Oncology (ASCO). In addition, Dr. Tonorezos led a recent international effort to develop recommendations for adult survivors of heritable retinoblastoma.



Mr. Austin Waters is currently a doctoral student in Health Policy and Management at the University of North Carolina at Chapel Hill with a background in public health, sociology, and cancer health services research from Huntsman Cancer Institute and the University of Utah. Austin's T32 predoctoral fellowship focuses on the multi-level drivers of economic and mental health disparities among LGBTQ+ cancer populations. Austin is passionate about community centered research from an socioecological perspective and is dedicated to health equity in all forms.



Dr. Andrew Wood is an Assistant Professor of Counseling at the University of Cincinnati in Cincinnati, Ohio. He has been researching cancer and cancer stigma since 2012, when he obtained his degree in Counselor Education and Supervision from the University of Central Florida. He is particularly interested in prostate cancer, including the experience of partners of those with cancer and the couple's psychosocial experience.



Dr. Lawrence Yang is Professor and Vice Chair of the Department of Social and Behavioral Sciences at NYU- School of Global Public Health. Dr. Yang also is Founding Director of the Global Mental Health and Stigma Program where he administers a generous donor gift from the Li Ka Shing Foundation and is Associate Director for the University-Wide Global Center for Implementation Science at NYU. Dr. Yang's research focuses on two main areas: 1) Stigma, Global Mental Health, and Implementation Science; and 2) Cognition of Untreated Psychosis. A major area of Dr. Yang's research focuses on addressing stigma of health conditions; during his NIMH K-award, he formulated theoretical work on how culture relates to stigma, and he also was PI of a recently-completed 5-year NIMH R01 grant examining the neurocognitive and social

**GLOBAL CANCER STIGMA RESEARCH WORKSHOP – SEPTEMBER 28-29, 2022,
[SPEAKER BIOGRAPHIES]**

cognitive underpinnings of the potentially transformative "clinical high-risk state for psychosis" designation.

Dr. Yang has received seven national awards, most recently the 2021 Maltz Prize for Innovative and Promising Schizophrenia Research from the Brain and Behavioral Research Foundation, for his work.
